Back

DNA methylation of ADAMTS7 gene promoter in direct oral anticoagulant-induced bleeding in patients with atrial fibrillation

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation: minimising bleeding Anticoagulants ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Miss Natalia Atzemian

Center for Translational and Experimental Cardiology (CTEC), Zurich (Switzerland)

5 More presentations in this session

Presentation thumbnail
Outcomes with oral anticoagulation resumption or discontinuation after an anticoagulation-related event in patients with atrial fibrillation
Doctor G. Denas (Motta Di Livenza, IT)
Abstract Slides Video
Presentation thumbnail
Effectiveness of high- versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated intracranial hemorrhage
Doctor W. Baker (Storrs, US)
Abstract Slides Video
Presentation thumbnail
Factor XI inhibitors in early clinical trials: a meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Detection and management of clinically relevant drug-drug interactions with direct oral anticoagulants in ambulatory care: a prospective interventional study in community pharmacies
Mr A. Capiau (Ghent, BE)
Abstract Slides Video
Presentation thumbnail
Comparison of Antithrombotic Regimens after Left Atrial Appendage Occlusion: A Systematic Review and Network Meta-analysis
Doctor L. KUBRUSLY (Curitiba, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulation: minimising bleeding

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Methylome of circulating cell free DNA as a novel biomarker tool: from acute coronary syndrome to broader risk stratification of cardiovascular disease
thumbnail
Congress Presentation
Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin
thumbnail
Congress Presentation
Patient characteristics and real-world outcomes among atrial fibrillation patients treated with direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in Spain

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources